NeuroSense Reports Results From 12-Month Analysis Of Its PARADIGM Phase 2b Study Evaluating PrimeC In ALS Patients; Disease Progression Was Slowed By 36% V Placebo
NeuroSense Reports Results From 12-Month Analysis Of Its PARADIGM Phase 2b Study Evaluating PrimeC In ALS Patients; Disease Progression Was Slowed By 36% V Placebo
NeuroSense报告了其PARADIGM 2b期研究中PrimeC在ALS患者中的12个月分析结果；疾病进展较安慰剂缓慢了36%。
NeuroSense Reports Results From 12-Month Analysis Of Its PARADIGM Phase 2b Study Evaluating PrimeC In ALS Patients; Disease Progression Was Slowed By 36% V Placebo
NeuroSense报告了其PARADIGM 2b期研究中PrimeC在ALS患者中的12个月分析结果；疾病进展较安慰剂缓慢了36%。